Detection method for glycosylation of inactivated virus vaccine product based on agglutinin affinity
Through enzyme-linked immunosorbent assays of specific antibodies and fluorescein-labeled lectin, the complexity and cost of protein glycosylation modification detection in inactivated viral biological products is solved, and efficient and accurate glycosylation characteristics are achieved Testing is suitable for rapid quality control in vaccine production.
Patent Information
- Application Number
- CN202411034903.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
AI Technical Summary
The existing glycosylation detection methods have problems such as complex operation, high cost, low throughput and poor targeting for protein glycosylation modification characteristics of inactivated viral biological products, which are difficult to meet the rapid, accurate and efficient vaccine production. quality control requirements.
The targeted proteins in the sample were enriched by microplate coated with specific antibody, and combined with fluorescein-labeled lectin for enzyme-linked immunosorbent assay. By analyzing the fluorescence intensity ratio of different lectins, the targeted molecule was obtained. The glycosylation modification situation achieves semi-quantitative detection.
This method achieves efficient, accurate, sensitive, low-cost and high-throughput semi-quantitative detection, simplifies the operation process, improves the accuracy and repetition of the detection, and is suitable for the industrial production of inactivated virus vaccines, helping to explore sugar Effects of chain structure differences on vaccine immunogenicity.
Smart Images

Figure CN118914548A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for detecting the glycosylation of an inactivated virus vaccine product based on lectin affinity, and belongs to the technical field of glycosylation detection and analysis. Background Art
[0002] Protein glycosylation is a common post-translational modification of proteins. Proteins are endowed with monosaccharide or oligosaccharide chains at specific sites through the glycosylation modification system in the endoplasmic reticulum and Golgi apparatus, thus having multiple biological functions. More than half of biopharmaceutical products are glycosylated, including monoclonal antibodies, fusion proteins, cytokines, recombinant protein vaccines, and inactivated virus vaccines.
[0003] Currently, the main glycomics analysis methods include liquid chromatography, mass spectrometry (MS), and lectin array.
[0004] Liquid chromatography usually involves digesting N-glycan chains from glycoproteins with glycosidases, enriching the chains with adsorption columns, labeling them with fluorescent reagents (usually 2-aminopyridine), and finally separating and analyzing them using a liquid phase system. The separation principle of this method is based on differences in the chemical structure of glycans; that is, in normal phase (hydrophilic interaction) chromatography, separation depends primarily on the size of each glycan (roughly the number of hydroxyl groups), while in reverse phase chromatography, separation is based on the hydrophobicity of each glycan, but the actual mechanism is much more complicated. This method is basically applicable to various glycans after pyridinyl amidation, and has been proven to be able to identify more than 500 glycans. However, each chromatographic analysis of a single sample requires a relatively long time (usually 1 hour), so the throughput is low; the preliminary processing requires digestion, enrichment and labeling of sugar chains, which is complicated and time-consuming. Each step of the operation will cause sugar chain loss or contamination, affecting the final experimental results. The experimental stability depends on the actual operation ability of the operator. Virus samples are relatively rare and complex in composition, and there is no way to achieve effective sugar group digestion and enrichment like simple protein samples; and it is necessary to purchase sample processing kits, the reagents used are highly toxic and expensive, and the liquid phase system needs to be equipped with a fluorescence detector, so the detection cost is relatively high.
[0005] The applicability of mass spectrometry to complex glycans was first realized through tandem mass spectrometry. This method is very useful for confirming and estimating the structure of glycans, including amino glycans, and has certain advantages in accuracy (resolution). However, mass spectrometry not only requires pretreatment of complex samples (including protein denaturation, enzyme cleavage), but also cannot reveal the characteristics of component sugars alone. Subsequent data processing is also very complicated, and because mass spectrometry instruments are expensive, they are not suitable for ordinary laboratories.
[0006] Lectin array is a new platform for high-throughput analysis of glycans and glycoproteins using lectin groups fixed on solid surfaces. Lectin microarray can evaluate the overall characteristics of glycoproteins and cell glycosylation by analyzing the biochemical interactions between polysaccharides and multiple lectins. The advantages of this method are easy operation, high throughput, and rapidity. However, it has high requirements for sample purity and concentration, and is only applicable to purified protein solutions. It is difficult to accurately detect virus purification solutions with low protein concentrations; and it is not specific. Lectin array chips are extremely sensitive to sugars and glycoproteins. Therefore, the lectins on the solid surface of the lectin array will capture possible glycoproteins in the sample and affect the results. In addition, this method requires the purchase of lectin array chips and matching instruments and equipment, and the detection cost is high.
[0007] Inactivated viruses retain the antigenic proteins of the virus, remove the pathogenicity of the virus, and promote immune cells to produce specific antibodies against the antigenic proteins, thereby achieving the purpose of preventing or treating the virus. Under normal circumstances, the antigenic proteins of inactivated viruses are all glycoproteins. Sugar chains attached to proteins can ensure the proper folding of proteins and protect antigenic epitopes from recognition by immune cells or antibodies. However, due to the lack of fixed patterns for monosaccharide or oligosaccharide chain modification and diverse structures, inactivated viruses are usually virus particles, that is, polymer structures of multiple viral proteins. There are usually several or dozens of protein types and the composition is relatively complex. Unlike single protein samples, virus samples have a lower concentration, usually only one percent or one thousandth of a single protein sample, so analysis is more difficult, and the glycosylation modification analysis method still needs to be studied in depth. At present, vaccine production is mainly based on viral vaccine products. Considering the influence of sugar groups on the immunogenicity of viral vaccine products, future viral vaccine products may need to detect the content of sugar components as a quality control method. Therefore, it is necessary to establish an effective, convenient and rapid identification method for the quality control of viral vaccines. Summary of the invention
[0008] Problem that the invention aims to solve
[0009] The purpose of the present invention is to solve the problem of detecting the glycosylation modification characteristics of proteins in inactivated virus biological products, and to provide a method for rapid detection of the glycosylation modification characteristics of inactivated viruses. The method is not only simple to operate and low in cost, but also has high accuracy and repeatability, and has good application prospects in biological product detection.
[0010] Solutions for solving problems
[0011] To achieve the above object, the present invention is implemented by the following technical scheme: first prepare a microplate coated with a specific antibody for enriching the target protein in the sample, then add the inactivated virus sample into the microplate for capture and enrichment, add the lectin labeled with fluorescein into the microplate as needed, and then use a multifunctional microplate reader to irradiate the microplate with 495nm excitation light to detect the fluorescence intensity of the emitted light at 521nm. By analyzing the proportional relationship between the fluorescence values of ConA wells and AAL, LTL, GS-II, ECA, and PSL wells, the glycosylation modification of the target molecule is obtained.
[0012] The present invention is a semi-quantitative detection method for glycosylation enzyme-linked immunosorbent assay of inactivated virus vaccine products developed based on lectin affinity. The results show that this method can semi-quantitatively detect the glycosylation characteristics of inactivated viruses in an efficient, accurate, sensitive, low-cost and high-throughput manner. The equipment used is relatively common, the sample loss is small, the operation is simple, easy to repeat, and the accuracy is high. It is conducive to rapid detection in the vaccine production process and batch difference comparison. The present invention provides a stable, effective, convenient and high-throughput glycosylation characteristic difference analysis method for the industrial production of inactivated virus vaccines, which is helpful to explore the influence of the differentiation of the inactivated virus sugar chain structure on the immunogenicity of the vaccine.
[0013] The present invention provides a method for detecting protein glycosylation modification in a virus vaccine, wherein the virus vaccine comprises inactivated virus particles or attenuated live virus particles;
[0014] The method comprises:
[0015] The step of capturing viral particles in antibody-immobilized viral vaccines;
[0016] The step of binding of lectins to viral particles in viral vaccines;
[0017] A step of measuring fluorescence intensity; and
[0018] Step-by-step method for glycan content calculation;
[0019] Preferably, the lectin comprises Con-A;
[0020] Optionally, the lectin further comprises at least one of AAL, LTL, GS-II and ECA;
[0021] Preferably, the lectin is tagged with fluorescein.
[0022] In some embodiments, in the step of capturing antibodies to fix viral particles in the viral vaccine, the biological titer of the viral vaccine is not less than 150mIU / ml;
[0023] Preferably, the biological potency of the viral vaccine is 150mIU / ml to 2500mIU / ml.
[0024] In some embodiments, the step of binding the lectin to the virus particles in the virus vaccine comprises binding the virus particles immobilized with the capture antibody to the lectin by affinity.
[0025] In some embodiments, the virus particles in the virus vaccine have sugar chains;
[0026] Optionally, the sugar chain consists of an N-linked glycan consisting of a pentasaccharide core comprising two N-acetylglucosamines and three mannoses;
[0027] Optionally, the pentasaccharide core is linked to a glycosyl or glycosamine comprising at least one of glucose, galactose, mannose and fucose.
[0028] In some embodiments, in the system where lectin binds to viral particles, the concentration of lectin used is higher than 2.5 μg / ml.
[0029] In some embodiments, the viral vaccine comprises a rabies vaccine.
[0030] In some embodiments, the fluorescence intensity is measured using a multifunctional microplate reader.
[0031] In some embodiments, the fluorescence intensity at a wavelength of 510 to 520 nm is detected under the condition that the excitation light wavelength is 490 to 500 nm.
[0032] In some embodiments, the glycan content is calculated as follows:
[0033] Glycan content (%) = [lectin A (mean fluorescence intensity) - negative control (mean fluorescence intensity)] / [lectin B (mean fluorescence intensity) - negative control (mean fluorescence intensity)];
[0034] The lectin A includes at least one of AAL, LTL, GS-II and ECA;
[0035] The lectin B is Con-A;
[0036] The negative control is a buffer without adding virus vaccine;
[0037] The average fluorescence intensity is the average of the fluorescence intensities of at least 3 sets of repeated experiments.
[0038] In some embodiments,
[0039] When lectin A is AAL, the proportion of terminal fucose in the sugar chain of the virus particle can be obtained;
[0040] When lectin A is LTL, the proportion of branched fucose in the sugar chain of the virus particle can be obtained;
[0041] When lectin A is GS-II, the proportion of terminal glucosamide in the sugar chain of the virus particle can be obtained;
[0042] When lectin A is ECA, the proportion of terminal acetylgalactosamine in the sugar chain of the virus particle can be obtained.
[0043] Effects of the Invention
[0044] 1. The detection method provided by the present invention solves the shortcomings of analytical methods such as high performance liquid chromatography and tandem mass spectrometry, such as complex technical routes, difficult operations, and time-consuming.
[0045] 2. The detection method provided by the present invention solves the shortcomings of the lectin array analysis method, such as high detection cost and poor targeting.
[0046] 3. The reagents used in the detection method provided by the present invention only include: high-binding microplate, specific antibody, fluorescent labeled lectin and PBS buffer, the reagents used are easy to buy and the method of use is simple. The detection equipment is only a multifunctional microplate reader, and the equipment cost is low.
[0047] 4. The detection method provided by the present invention greatly compresses the experimental steps and simplifies the experimental operation. The detection can be carried out after the lectin incubation is completed. It has the advantages of convenient, efficient, accurate, reproducible, low-cost and high-throughput detection of inactivated viral glycosylation characteristics.
[0048] 5. The detection method provided by the present invention is targeted, uses antibodies to capture viruses in samples, has high test specificity, and can analyze complex biological samples, such as virus particles containing complex protein components.
[0049] 6. The detection method provided by the present invention can be applied to batch detection in the inactivated virus production process and the investigation of batch-to-batch consistency; at the same time, it provides an effective method for glycosylation analysis in inactivated virus vaccine biological products, which is conducive to the study of the effect of glycosylation characteristics on vaccine immunogenicity.
[0050] 7. The detection method provided by the present invention is close to the results of the LC-MS / MS detection method, with an error of no more than ±10%, showing a good result matching degree; it can also be combined with mass spectrometry data to selectively select fluorescently labeled lectins for detection, thereby reducing workload and saving resources.
[0051] 8. The microplate reader used in the detection method provided by the present invention is equipped with a multi-channel fluorescence detection system, which is suitable for rapid detection of fluorescent samples. Ordinary microplate readers do not have this detector, so it is necessary to use secondary antibodies to incubate the samples before testing on the machine.
[0052] 9. The fluorescently labeled lectin used in the detection method provided by the present invention can effectively shorten the operation steps and time. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 The figure is a flow chart and a data calculation formula of the method of the present invention.
[0054] Figure 2 The glycoform structure targeted by the lectin used in the present invention; the green circle in the figure represents mannose, the square represents glucose, the triangle represents fucose, and the yellow circle represents galactose.
[0055] Figure 3 The linear relationship and minimum detection limit of concanavalin A in detecting inactivated rabies virus vaccine.
[0056] Figure 4 This is the error fluctuation range of the fluorescent labeled lectin detection of terminal fucose in inactivated rabies virus vaccine.
[0057] Figure 5 The fluorescence signal intensity of the inactivated rabies virus vaccine after deglycosylation was detected by lectin.
[0058] Figure 6 To compare the results of LC-MS / MS method and lectin Elisa method in detecting glycosylation modification of rabies virus vaccine.
[0059] Figure 7 The results are shown in Figure 2.5 μg / ml of fluorescein-labeled concanavalin A for detecting inactivated rabies virus vaccine. DETAILED DESCRIPTION
[0060] Various exemplary embodiments, features and aspects of the present invention will be described in detail below. The word "exemplary" used here means "used as an example, embodiment or illustrative". Any embodiment described here as "exemplary" is not necessarily interpreted as being superior or better than other embodiments.
[0061] In addition, in order to better illustrate the present invention, numerous specific details are provided in the following specific embodiments. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present invention.
[0062] Unless otherwise stated, the units used in this specification are all international standard units, and the numerical values and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.
[0063] In this specification, the word "may" means both performing a certain process and not performing a certain process.
[0064] In this specification, the references to "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", etc., mean that the specific elements (e.g., features, structures, properties and / or characteristics) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not exist in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner.
[0065] Throughout the specification, “optional” and “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0066] In this specification, the numerical range expressed using "a numerical value A to a numerical value B" means a range including the endpoints numerical values A and B.
[0067] Glycosylation mainly refers to the enzymatic process of attaching glycans to proteins, lipids or other organic molecules and is the most common protein post-translational modification (PTM).
[0068] Lectins are a class of proteins that are widely present in nature and have specific recognition for sugar chain structures. Their working principle is to characterize the glycosylation level of glycoproteins in samples by detecting sugar chain structures that are affinity for one or more lectins. Changes in glycosylation modification can regulate immune function or participate in immune inflammatory responses, etc., and these lectins can be used as diagnostic markers to characterize disease states.
[0069] The technical solution of the present invention is specifically described below:
[0070] At present, the detection of protein glycosylation usually requires pure protein. The detection of protein glycosylation in virus vaccines usually requires the extraction of glycoprotein from the virus, and then the glycoprotein is detected. The purity and concentration of the glycoprotein are both highly required, and the detection process is relatively complicated. The present invention directly uses inactivated virus as the detection object, incubates the inactivated virus sample with the capture antibody, and then undergoes affinity of the lectin labeled with fluorescein and fluorescence detection steps of LC-MS, and finally calculates the relative content of polysaccharides of different modified types.
[0071] The present invention provides a method for detecting protein glycosylation modification in a virus vaccine, wherein the virus vaccine comprises inactivated virus particles or attenuated live virus particles;
[0072] The method comprises:
[0073] The step of capturing viral particles in antibody-immobilized viral vaccines;
[0074] The step of binding of lectins to viral particles in viral vaccines;
[0075] The step of measuring fluorescence intensity; and
[0076] Steps for glycan content calculation.
[0077] In some embodiments, the viral particle comprises a complex protein component.
[0078] In the present invention, the inactivated virus particles or attenuated live virus particles are the main effective ingredients of the inactivated vaccine or attenuated vaccine, contain all the virus structural parts, are close to or equal to natural virus particles, and their surface glycoproteins can induce human immune response to produce neutralizing antibodies with protective effects.
[0079] Steps for capturing viral particles in antibody-immobilized viral vaccines
[0080] In some embodiments, in the step of fixing the virus particles in the virus vaccine with the capture antibody, there is no particular limitation on the virus vaccine, and the virus vaccine can be a purified virus solution inactivated during the production process, or a sample of a finished inactivated virus vaccine product after ultrafiltration purification. The titer of the virus vaccine is not less than 150mIU / ml; preferably, the titer of the virus vaccine is not less than 150mIU / ml, more preferably 150mIU / ml to 2500mIU / ml, within which range the fluorescence intensity can be kept linearly correlated with the virus titer.
[0081] In some specific embodiments, the virus vaccine is a virus vaccine carrying a sugar chain; the sugar chain comprises an N-linked polysaccharide with a pentasaccharide core containing two N-acetylglucosamines and three mannoses; further, the N-linked polysaccharide further comprises a glycosyl or glycosamine composed of one or more of glucose, galactose, mannose and fucose connected to the pentasaccharide core; illustratively, the glycosyl or glycosamine comprises fucosyl, glucosamine, galactosamine, etc. Furthermore, the fucosyl, glucosamine, and galactosamine can be further connected to the above-mentioned glycosyl or glycosamine composed of one or more of glucose, galactose, mannose and fucose.
[0082] In some exemplary embodiments, the viral vaccine comprises rabies vaccine (CTN1 strain).
[0083] In the present invention, there is no particular limitation on the capture antibody, as long as it can bind to the corresponding viral vaccine or the viral particles in the viral vaccine. For example, for rabies vaccine, rabies virus monoclonal antibody MAb0322 can be used as the capture antibody.
[0084] In some optional embodiments, the antibody fixation step is further included, and the antibody is fixed on the microwell plate before the antibody capture step of the virus vaccine. Specifically, the antibody is fixed using a flat-bottom microwell strip and a support that can efficiently bind biomacromolecules and is easy to separate; more specifically, the antibody is diluted with PBS to a concentration of at least 0.1 μg / ml for use, 100 μl per well, and reacted at 4°C for 16 hours.
[0085] Steps in the binding of lectins to viral particles in viral vaccines
[0086] Furthermore, the step of combining the lectin with the virus particles in the virus vaccine includes binding the virus particles fixed with the capture antibody to the lectin.
[0087] In some preferred embodiments, the lectin includes concanavalin A (Con-A). In some optional embodiments, the lectin also includes at least one of A. aurantifolia agglutinin (AAL), Lotus japonicus agglutinin (LTL), GS-II, and Erythrina cristatum agglutinin (ECA); preferably, the lectin carries a fluorescein tag. The lectin can bind to the sugar chain on the surface of the virus particle.
[0088] In some specific embodiments, Con-A can specifically bind to free hydroxyl groups on glycoproteins, especially α-mannose which is a component of the core oligosaccharide of membrane glycoproteins. Therefore, Con-A can be used as a reference to calculate the relative content of different glycans.
[0089] In some specific embodiments, the lectin AAL can bind to the terminal fucosyl; the lectin LTL can bind to the branched α-L-fucosyl and α-D-fucosyl; the lectin GS-II can bind to the terminal non-reduced α- or β-linked N-acetyl-D-glucosamine; and the lectin ECA can bind to the terminal β-galactosamine.
[0090] In some more specific embodiments, the fluorescence intensity of the sample added with Con-A is used as a reference, the negative control is used to remove the background value, and then combined with the fluorescence intensity of the sample added with AAL, LTL, GS-II, and ECA to measure the content of various types of polysaccharides therein.
[0091] In some embodiments, in the system where the lectin is bound to the virus particles in the virus vaccine, the concentration of the lectin is greater than 2.5 μg / ml, preferably not less than 5 μg / ml.
[0092] Steps for fluorescence intensity measurement
[0093] In some embodiments, a multifunctional microplate reader is used to detect the intensity of the fluorescence signal; specifically, the excitation light wavelength is 490 to 500 nm, and the absorbance value at a wavelength of 510 to 520 nm is used as the fluorescence signal value.
[0094] In some embodiments, the multifunctional microplate reader is equipped with a multi-channel fluorescence detection system, which is suitable for rapid detection of fluorescent samples.
[0095] Steps for glycan content calculation
[0096] In some embodiments, based on the intensity of the obtained fluorescence signal, the glycan content satisfies the following relationship:
[0097] Glycan content % = [AAL / LTL / GS-II / ECA (mean fluorescence intensity) - negative control (mean fluorescence intensity)] / [ConA (mean fluorescence intensity) - negative control (mean fluorescence intensity)];
[0098] Wherein, the negative control is PBS buffer without adding virus vaccine;
[0099] The average fluorescence intensity is the average of the fluorescence intensities of at least 3 sets of repeated experiments.
[0100] In some specific embodiments, the relative contents of terminal fucose, branched fucose, terminal glucosamide, terminal acetylgalactosamine and other polysaccharides in the sugar chain of the virus particles can be calculated according to the fluorescence intensity values of lectins AAL, LTL, GS-II or ECA.
[0101] Example
[0102] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0103] The capture antibody used in the above examples is rabies virus monoclonal antibody MAb0322, purchased from Nanjing Miaodi Biotechnology; the microporous plate used is purchased from Corning; the PBS and carbonate solution raw materials used are purchased from Solebow; the fluorescein-labeled lectins used (fluorescein-labeled ConA, fluorescein-labeled AAL, fluorescein-labeled LTL, fluorescein-labeled GS-II, fluorescein-labeled ECA) are all purchased from Vector Company, and the PNGase enzyme used is purchased from Beyotime Company.
[0104] Example 1: Detection of the linear range and minimum detection limit of the method of the present invention
[0105] 1) Immobilizing specific antibodies on microplates to prepare virus capture matrix plates;
[0106] The capture antibody was diluted to 1 μg / ml with 0.05 M carbonate, mixed with a mixer, and then added to a microplate (high adsorption detachable microplate, 57 wells in total) at a loading volume of 100 μl per well. The microplate was sealed with a sealing bag and incubated at 4°C overnight.
[0107] 2) The next day, the antibody-fixed microplate was washed three times using PBST buffer using an automatic plate washer.
[0108] 3) After washing the microplate, add 100 μl of blocking solution (1.5% BSA in PBS) to each well.
[0109] 4) After blocking, wash the microplate three times with PBST buffer and pat dry with absorbent paper to remove excess water.
[0110] 5) The three batches of rabies vaccine samples were diluted in PBS buffer according to their biological potency (the initial potency of the vaccine was 2.5 IU / ml), i.e., original / 2, original / 4, original / 8, original / 16, and original / 32. After dilution, the samples were added to a microplate at a loading volume of 100 μl per well. Three wells were spotted for each dilution, and the samples were quickly incubated at 37°C for 1 h. After the reaction was completed, the samples were washed with PBST buffer.
[0111] 6) After incubation, wash the microplate three times with PBST and pat dry the excess water on absorbent paper; take out the fluorescein-labeled concanavalin A (ConA) solution, dilute it 1000 times to 5 μg / ml with PBS buffer, add 100 μl of concanavalin A dilution to each well, and react at room temperature in the dark for 1 hour.
[0112] 7) After the reaction, wash the microplate three times with PBST, pat dry the excess water on absorbent paper, use a multifunctional microplate reader, select an excitation wavelength of 495 nm, detect the absorbance at a wavelength of 515 nm, and take the average fluorescence signal value of the three wells under each dilution gradient for standard curve calculation.
[0113] Specific test results such as Figure 3 As shown, the horizontal axis is the biological titer of rabies virus (mIU), and the vertical axis is the absorbance value at the detection wavelength of 515nm. In this example, PBS buffer without adding virus vaccine sample was used as a negative control. The results showed that the lectin fluorescence signal value was linearly correlated with the virus titer, and the three batches of vaccine samples R 2 >0.99, the linear range is 150mIU / ml~2500mIU / ml, and the minimum detection limit is 150mIU / ml.
[0114] Example 2: Test of the relationship between the error fluctuation range of fucose ratio in virus vaccine samples and biological potency Test
[0115] 1) Dilute the capture antibody to 1 μg / ml with 0.05 M carbonate, mix well with a mixer, and add 100 μl per well to a microplate (high adsorption detachable microplate, 51 wells in total). Seal the microplate with a sealing bag and incubate at 4°C overnight.
[0116] 2) The next day, the antibody-fixed microplate was washed three times using PBST buffer using an automatic plate washer.
[0117] 3) After washing the microplate, add 100 μl of blocking solution (1.5% BSA in PBS) to each well.
[0118] 4) After blocking, wash the microplate three times with PBST buffer and pat dry with absorbent paper to remove excess water.
[0119] 5) The three batches of rabies vaccine samples were diluted in PBS buffer according to their biological potency (the initial potency of the vaccine was 13.8 IU / ml), i.e., original / 2, original / 4, original / 8, original / 16, original / 32, original / 64, and original / 124. After dilution, 100 μl of sample was added to each well of a microplate. Three wells were spotted for each dilution, and the samples were quickly incubated at 37°C for 1 h. After the reaction was completed, the samples were washed with PBST buffer.
[0120] 6) After the incubation, wash the microplate three times with PBST and pat dry the excess water on absorbent paper; take out the fluorescein-labeled ConA solution, dilute it to 5 μg / ml with PBS buffer, and add 100 μl of ConA diluent to each of the 24 wells in the microplate; take out the fluorescein-labeled AAL solution and dilute it to 5 μg / ml with PBS buffer, and add 100 μl of AAL diluent to each of the other 24 wells of the microplate, and react at room temperature in the dark for 1 hour.
[0121] 7) After the reaction, wash the microplate three times with PBST, pat dry the excess water on absorbent paper, use a multifunctional microplate reader, select an excitation wavelength of 495 nm, detect the absorbance at a wavelength of 515 nm, and take the average fluorescence signal value of 3 wells in each dilution gradient under the reaction of ConA and AAL solution for percentage analysis.
[0122] Specific test results such as Figure 4 As shown, the horizontal axis is the biological titer of rabies virus (mIU), and the vertical axis is the ratio of AAL / ConA at the detection wavelength of 515nm. In this example, PBS buffer without adding virus vaccine sample is used as a negative control, and the results show that the ratio of AAL / ConA is in the range of 860mIU / ml to 13800mIU / ml, which is stable within 30%±5%.
[0123] Example 3: Detection of the specificity of the method of the present invention
[0124] 1) Dilute the capture antibody to 1 μg / ml with 0.05 M carbonate, mix well with a mixer, and add 100 μl per well to a microplate (high adsorption detachable microplate, 6 wells in total). Seal the microplate with a sealing bag and incubate at 4°C overnight.
[0125] 2) The next day, the antibody-fixed microplate was washed three times using PBST buffer using an automatic plate washer.
[0126] 3) After washing the microplate, add 100 μl of blocking solution (1.5% BSA in PBS) to each well.
[0127] 4) After blocking, wash the microplate three times with PBST buffer and pat dry with absorbent paper to remove excess water.
[0128] 5) Take 1 ml of rabies vaccine sample from the same batch and divide it into two portions of 500 μl each. One of the samples is digested with glycosidase (PNGase, 500 U / μl) at 37°C overnight; the other remains unchanged as a positive control. After digestion, add the vaccine sample to the microplate at a loading volume of 100 μl per well, repeat 3 wells for each sample, quickly incubate at 37°C for 1 h, and wash 3 times with PBST buffer after the reaction is completed.
[0129] 6) After incubation, wash the microplate three times with PBST and pat dry the excess water on absorbent paper; take out the fluorescein-labeled concanavalin A (ConA) solution, dilute it to 5 μg / ml with PBS buffer, add 100 μl of concanavalin A dilution to each well, and react at room temperature in the dark for 1 hour.
[0130] 7) After the reaction, wash the microplate three times with PBST, pat dry the excess water on absorbent paper, use a multifunctional microplate reader, select an excitation wavelength of 495 nm, detect the absorbance at a wavelength of 515 nm, and calculate the average fluorescence signal value of the three wells under each dilution gradient.
[0131] Specific test results such as Figure 5 The horizontal axis is the treatment method, and the vertical axis is the absorbance value at the detection wavelength of 515 nm. In this example, PBS buffer without adding the virus vaccine sample is set as a negative control, and the virus vaccine sample without adding glycosidase is set as a positive control. The results show that after glycosidase treatment, the lectin signal value of the virus vaccine is significantly reduced. Therefore, the method of the present invention is more suitable for virus vaccine samples carrying sugar chains.
[0132] Example 4: Detection of glycosylation characteristic structures of virus vaccine samples using the following steps
[0133] 1) Dilute the capture antibody to 1 μg / ml with 0.05 M carbonate, mix well with a mixer, and add 100 μl per well to a microplate (high adsorption detachable microplate, 48 wells in total). Seal the microplate with a sealing bag and incubate at 4°C overnight.
[0134] 2) The next day, the antibody-fixed microplate was washed three times using PBST buffer using an automatic plate washer.
[0135] 3) After washing the microplate, add 100 μl of blocking solution (1.5% BSA in PBS) to each well.
[0136] 4) After blocking, wash the microplate three times with PBST buffer and pat dry with absorbent paper to remove excess water.
[0137] 5) Take three batches of vaccine samples, add the vaccine samples to the microplate at a loading volume of 100 μl per well, repeat 15 wells for each batch, incubate at 37° C. for 1 h, and wash three times with PBST buffer after the reaction is completed.
[0138] 6) After the incubation, wash the microplate three times with PBST and pat dry the excess water on absorbent paper; take out the fluorescein-labeled concanavalin A (ConA) solution, dilute it 1000 times to 5 μg / ml with PBS buffer, and add 100 μl of concanavalin A dilution solution to each batch, for a total of 9 wells; take out the fluorescein-labeled AAL solution, dilute it to 5 μg / ml with PBS buffer, and add 100 μl of AAL dilution solution to each batch, for a total of 9 wells;
[0139] Take fluorescein-labeled LTL, dilute it to 5 μg / ml with PBS buffer, add 100 μl of AAL dilution to each batch, for a total of 9 wells;
[0140] Take fluorescein-labeled GS-II, dilute it to 5 μg / ml with PBS buffer, add 100 μl of AAL diluent to each batch, for a total of 9 wells;
[0141] Take the fluorescein-labeled ECA solution, dilute it to 5 μg / ml with PBS buffer, and add 100 μl of AAL dilution solution to each batch, for a total of 9 wells;
[0142] 7) After the reaction, wash the microplate three times with PBST, pat dry the excess water on absorbent paper, use a multifunctional microplate reader, select an excitation wavelength of 495 nm, detect the absorbance at a wavelength of 515 nm, and take the average fluorescence signal value of the three wells under each dilution gradient for standard curve calculation.
[0143] Specific test results such as Figure 6 The horizontal axis is the treatment method, and the vertical axis is the absorbance value at the detection wavelength of 515nm. In this example, PBS buffer without adding virus vaccine samples was used as a negative control. The results showed that the terminal fucose of the rabies virus vaccine accounted for 23.2±6.6%, the branched fucose accounted for 6.9±5.2%, the terminal glucosamide accounted for 5.4%±3.7%, and the terminal acetylgalactosamine accounted for 79.8±8.5%. At the same time, the difference between the three batches of vaccines was controlled within 10%.
[0144] 8) Comparison of mass spectrometry (LC-MS / MS) methods
[0145] Mass spectrometry was also used to detect glycosylation modifications in the samples.
[0146] The sample was treated by ultrafiltration tube enzymatic hydrolysis. At least 100 μg of sample solution was added to a 10 kDa ultrafiltration tube, centrifuged at high speed until the filter membrane was dry, 90 μl of denaturant 7 M guanidine hydrochloride and 2 μl of reducing agent 1 M dithiothreitol were added, vortexed, incubated at 45 ° C for 30 minutes, 5 μl of iodoacetamide was added, vortexed; and placed in the dark at room temperature for 30 minutes. Centrifuged, the solution was replaced with 50 mM Tris-HCl (pH 7.6), and pancreatin was added. The mass ratio of the added amount to the protein was 1:50. The final solution was fixed to 100 μl, and the reaction was terminated by heating at 100 ° C for 10 minutes after overnight enzymatic hydrolysis at 37 ° C. The mass-to-charge ratio value detected by the liquid mass spectrometer was compared with the molecular weight of the G protein after trypsin digestion under theoretical calculation, and its N-glycan structure map was analyzed.
[0147] Mass spectrometry comparison results showed that the N254-N269 peptide segment of the CTN-1 strain rabies virus glycoprotein was glycosylated, and the N-glycan was two four-branched complex glycoforms with a fucose-modified structure. Figure 6 shown.
[0148] Compared with the mass spectrometry results, the method difference of the results measured by the method of the present invention is also ≤5%.
[0149] Comparative Example 1: When the lectin concentration is ≤2.5μg / ml, a good linear relationship cannot be maintained.
[0150] 1) Immobilizing specific antibodies on microplates to prepare virus capture matrix plates;
[0151] The capture antibody was diluted to 1 μg / ml with 0.05 M carbonate, mixed with a mixer, and then added to a microplate (high adsorption detachable microplate, 57 wells in total) at a loading volume of 100 μl per well. The microplate was sealed with a sealing bag and incubated at 4°C overnight.
[0152] 2) The next day, the antibody-fixed microplate was washed three times using PBST buffer using an automatic plate washer.
[0153] 3) After washing the microplate, add 100 μl of blocking solution (1.5% BSA in PBS) to each well.
[0154] 4) After blocking, wash the microplate three times with PBST buffer and pat dry with absorbent paper to remove excess water.
[0155] 5) The rabies vaccine samples from the same batch were diluted in PBS buffer according to their biological potency (the initial potency of the vaccine was 2500mIU / ml), i.e., original / 2, original / 4, original / 8, original / 16, and original / 32. After dilution, the samples were added to the microplate at a loading volume of 100μl per well. Each dilution was spotted in 3 wells, and the samples were quickly incubated at 37°C for 1h. After the reaction was completed, the samples were washed with PBST buffer.
[0156] 6) After incubation, wash the microplate three times with PBST and pat dry the excess water on absorbent paper; take out the fluorescein-labeled concanavalin A (ConA) solution, dilute it 2000 times to 2.5 μg / ml with PBS buffer, add 100 μl of concanavalin A dilution to each well, and react at room temperature in the dark for 1 hour.
[0157] 7) After the reaction, wash the microplate three times with PBST, pat dry the excess water on absorbent paper, use a multifunctional microplate reader, select an excitation wavelength of 495 nm, detect the absorbance at a wavelength of 515 nm, and take the average fluorescence signal value of the three wells under each dilution gradient for standard curve calculation.
[0158] Specific test results such as Figure 7As shown, the horizontal axis is the biological titer of rabies virus (mIU), and the vertical axis is the absorbance value at the detection wavelength of 515nm. In this example, PBS buffer without adding virus vaccine sample is used as a negative control. The results show that the linear relationship between the lectin fluorescence signal value and the virus titer is poor within the linear range of 75mIU / ml to 2500mIU / ml. 2 =0.93, which is less than 0.99. Therefore, the optimal concentration of lectin should be higher than 2.5 μg / ml.
Claims
1. A method for detecting protein glycosylation modification in a viral vaccine, characterized in that: The virus vaccine contains inactivated virus particles or attenuated live virus particles; The method comprises: The step of capturing viral particles in antibody-immobilized viral vaccines; The step of binding of lectins to viral particles in viral vaccines; A step of measuring fluorescence intensity; and Steps for glycan content calculation; Preferably, the lectin comprises Con-A; Optionally, the lectin further comprises at least one of AAL, LTL, GS-II and ECA; Preferably, the lectin is tagged with fluorescein.
2. The method according to claim 1, characterized in that In the step of capturing the virus particles in the antibody-fixed virus vaccine, the biological potency of the virus vaccine is not less than 150mIU / ml; Preferably, the biological potency of the viral vaccine is 150mIU / ml to 2500mIU / ml.
3. The method according to claim 1 or 2, characterized in that: The step of combining the lectin with the virus particles in the virus vaccine comprises the step of binding the virus particles fixed with the capture antibody to the lectin affinity.
4. The method according to any one of claims 1 to 3, characterized in that: The virus particles in the virus vaccine have sugar chains; Optionally, the sugar chain comprises an N-linked glycan having a pentasaccharide core comprising two N-acetylglucosamines and three mannoses; Optionally, the N-linked glycan further comprises a glycosyl or glycosamine consisting of at least one of glucose, galactose, mannose and fucose linked to the pentasaccharide core.
5. The method according to any one of claims 1 to 4, characterized in that: In the system where the lectin is bound to the virus particles in the virus vaccine, the concentration of the lectin is higher than 2.5 μg / ml.
6. The method according to any one of claims 1 to 5, characterized in that: The viral vaccines include rabies vaccines.
7. The method according to any one of claims 1 to 6, characterized in that: The fluorescence intensity was measured using a multifunctional microplate reader.
8. The method according to claim 7, characterized in that The fluorescence intensity at a wavelength of 510 to 520 nm was detected under the condition of an excitation light wavelength of 490 to 500 nm.
9. The method according to any one of claims 1 to 8, characterized in that: The polysaccharide content was calculated as follows: Glycan content (%) = [lectin A (mean fluorescence intensity) - negative control (mean fluorescence intensity)] / [lectin B (mean fluorescence intensity) - negative control (mean fluorescence intensity)]; The lectin A includes at least one of AAL, LTL, GS-II and ECA; The lectin B is Con-A; The negative control is a buffer without adding virus vaccine; The average fluorescence intensity is the average of the fluorescence intensities of at least 3 sets of repeated experiments.
10. The method according to claim 9, characterized in that When lectin A is AAL, the proportion of terminal fucose in the sugar chain of the virus particle can be obtained; When lectin A is LTL, the proportion of branched fucose in the sugar chain of the virus particle can be obtained; When lectin A is GS-II, the proportion of terminal glucosamide in the sugar chain of the virus particle can be obtained; When lectin A is ECA, the proportion of terminal acetylgalactosamine in the sugar chain of the virus particle can be obtained.
